GENE ONLINE|News &
Opinion
Blog

2025-03-02|

Study at University of Pittsburgh Explores Why Some with Down Syndrome Avoid Dementia

by Mark Chiang
Share To

A groundbreaking study conducted by the University of Pittsburgh’s Swanson School of Engineering is shedding light on why some individuals with Down syndrome (DS) maintain cognitive stability despite a high risk of developing Alzheimer’s disease (AD)-related dementia. This research could potentially benefit not only those within the DS community but also enhance broader understanding of Alzheimer’s disease.

Individuals with Down syndrome face a lifetime risk exceeding 90% for developing dementia as they age, primarily due to Alzheimer’s disease. However, there remains a subset of the DS population that does not follow this expected pattern. The University of Pittsburgh’s new study aims to uncover the factors contributing to this unexpected cognitive stability in certain individuals with DS.

The findings from this research may provide critical insights into both the progression and possible prevention strategies for Alzheimer’s disease among the general population as well as those with Down syndrome. By identifying why some individuals with DS do not develop dementia, researchers hope to apply these insights towards broader therapeutic approaches for Alzheimer’s disease.

Date: March 1, 2025

Newsflash | Powered by GeneOnline AI

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Lower Waist-to-Hip Ratio in Midlife Associated with Better Cognitive Function in Later Years
2025-03-14
Study Links Poor Sleep in Older Adults to Glymphatic System Disruption
2025-03-12
Immune Cells Exhibit Dual Functional Roles in Defense and Attack
2025-03-03
LATEST
AI’s Promise to Profits: How IBM is Maximizing Business ROI with Accelerated Computing
2025-03-19
Edge Computing: The Next Big Thing in AI and Automation
2025-03-19
Neurosurgery Now: NVIDIA’s Holoscan AI Brings Real-Time 3D Vision to Enhance Surgical Precision at 2025 GTC
2025-03-18
NVIDIA GTC 2025: BioMap’s xTrimo — The AI Model That’s Changing Biotech and Drug Discovery
2025-03-18
AstraZeneca Acquires Cell Therapy Company in $1 Billion Deal to Develop In Vivo Cancer Treatments
2025-03-18
Gene Therapy Achieves Complete Cure for Sickle Cell Anemia in New York Patient
2025-03-17
NICE Recommends New Endometriosis Treatment for NHS Patients
2025-03-14
EVENT
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
Scroll to Top